Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice 2018) in a single Japanese pulmonary hypertension center

Yamamoto, Keiko; Tanabe, Nobuhiro; Takahashi, Yukiko; Naito, Akira; Sekine, Ayumi; Suda, Rika; Jujo Sanada, Takayuki; Sugiura, Toshihiko; Shigeta, Ayako; Sakao, Seiichiro; Tatsumi, Koichiro

doi:10.1186/s12890-021-01623-2

Table 6 Baseline characteristics (Study 2: Conventional PH and borderline PH group in pre-capillary PH)

From: Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice 2018) in a single Japanese pulmonary hypertension center

Total	N	Conventional pre-capillry PH			n	Borderline pre-capillary PH			p-value
Age	489	56.1	±	15.2	22	58.2	±	13.9	0.5342
Sex(F/M)	489	347	/	142	22	15	/	7	0.7808
mPAP(mmHg)	489	43.7	±	11.7	22	23.0	±	1.2	< 0.0001
PVR (WU)	489	9.2	±	4.6	22	4.2	±	0.9	< 0.0001
PAWP(mmHg)	489	7.5	±	3.1	22	5.7	±	2.9	0.0057
CO(L/min)	489	4.3	±	1.2	22	4.2	±	0.9	0.5689
6MWD(m)	449	360.1	±	104.7	12	403.2	±	11.3	0.1704
VC,% predicted	444	86.7	±	21.2	17	86.0	±	28.6	0.8827
FEV1.0,% predicted	444	75.8	±	10.8	17	73.9	±	17.3	0.4922
DLCO/VA,% predicted	420	75.8	±	27.3	16	70.7	±	21.8	0.4577
PaO₂(mmHg)	476	64.4	±	21.5	22	74.6	±	14.2	0.0281
PaCO₂(mmHg)	476	38.2	±	6.1	22	41.4	±	9.3	0.0212
P_VO₂(mmHg)	475	34.4	±	4.7	22	37.1	±	3.7	0.0087
O₂ administration( +)			71(14.5%)				1(4.6%)		0.1348
AaDo₂(mmHg)	475	40.3	±	23.8	22	26.3	±	10.3	0.0063
WHO-FC (I/II/III/IV)		(6/231/241/11)				(0/17/5/0)			0.0344
Vasodilators( ±)	489	301	/	188	22	5	/	17	< 0.0001
Group 1
Age	123	47.9	±	17.8	3	51.0	±	66.0	0.0357
Sex(F/M)	123	99	/	24	3	2	/	1	0.1417
mPAP(mmHg)	123	44.8	±	12.0	3	23.3	±	0.6	< 0.0001
PVR (WU)	123	9.0	±	4.7	3	4.4	±	0.5	< 0.0001
PAWP(mmHg)	123	7.7	±	3.1	3	7.0	±	1.7	0.0359
CO(L/min)	123	4.7	±	1.5	3	3.8	±	0.7	0.1295
6MWD(m)	95	398.0	±	107.4	3	472.0	±	61.5	0.2394
VC,% predicted	111	85.6	±	16.9	3	91.4	±	9.5	0.8324
FEV1.0,% predicted	111	79.1	±	9.4	3	76.9	±	9.9	0.4183
DLCO/VA,% predicted	107	73.4	±	23.9	3	74.4	±	12.8	0.5192
PaO₂(mmHg)	121	72.6	±	17.9	3	82.3	±	3.6	0.0013
PaCO₂(mmHg)	121	36.6	±	5.3	3	39.3	±	0.7	0.0072
P_VO₂(mmHg)	120	37.3	±	4.8	3	39.8	±	1.4	0.0003
O₂ administration( +)			17(13.8%)				0(0%)		0.3479
AaDo₂(mmHg)	121	33.9	±	19.2	3	21.0	±	4.4	< 0.0001
WHO-FC (I/II/III/IV)	123		(3/79/40/1)		3		(0/3/0/0)		0.4546
Vasodilators( ±)	123	92	/	31	3	2	/	1	< 0.0001
Underlying diseases			(%)				(%)
IPAH/HPAH/PVOD/PCH		55	44.7			-	-
CTD		38	30.9			1	33.3
Congenital		16	13.0			1	33.3
Portal hypertension		12	9.8			0	0.0
drug/HIV		2	1.6			0	0.0
unknown			–			1	33.3
Group 3
Age	59	62.3	±	13.2	9	63.3	±	13.5	0.8404
Sex(F/M)	59	28	/	31	9	5	/	4	0.6506
mPAP(mmHg)	59	36.5	±	11.0	9	22.4	±	1.3	0.0003
PVR (WU)	59	7.4	±	5.2	9	4.0	±	0.8	0.0546
PAWP(mmHg)	59	4.5	±	3.2	9	5.7	±	3.7	0.12
CO(L/min)	59	4.4	±	1.2	9	4.3	±	1.2	0.8225
6MWD(m)	36	281.2	±	89.5	5	317.6	±	107.4	0.4098
VC,% predicted	52	59.8	±	24.2	7	66.9	±	33.5	0.4882
FEV1.0,% predicted	52	73.6	±	17.2	7	68.6	±	24.5	0.498
DLCO/VA,% predicted	43	42.0	±	30.0	6	51.9	±	18.7	0.4353
PaO₂(mmHg)	53	64.4	±	35.4	9	65.8	±	15.6	0.9052
PaCO₂(mmHg)	53	46.2	±	9.6	9	47.0	±	12.1	0.8248
P_VO₂(mmHg)	53	34.9	±	4.0	9	35.1	±	3.0	0.9152
O₂ administration( +)			17(28.8%)				1(11.1%)		0.2265
AaDo₂(mmHg)	52	31.4	±	42.9	9	28.5	±	13.7	0.8458
WHO-FC (I/II/III/IV)			(0/11/46/2)				(0/5/4/0)		0.0671
Vasodilators( ±)	59	35	/	24	9	0	/	9	0.0001
Underlying diseases			(%)				(%)
ILD		36	61.0			4	44.4
COPD		13	22.0			3	33.3
BE		6	10.2			1	11.1
Others		4	6.8			1	11.1
Group 4
Age	301	58.2	±	13.1	10	55.7	±	15.2	0.5475
Sex(F/M)	301	216	/	85	10	8	/	2	0.5551
mPAP(mmHg)	301	44.7	±	11.2	10	23.4	±	0.7	< 0.0001
PVR (WU)	301	9.6	±	4.4	10	4.3	±	1.1	0.0002
PAWP(mmHg)	301	7.5	±	3.1	10	5.3	±	2.4	0.0269
CO(L/min)	301	4.2	±	1	10	4.2	±	0.6	0.8073
6MWD(m)	254	357.8	±	99.4	4	458.5	±	80.4	0.0449
VC,% predicted	278	92.2	±	18.1	7	102.7	±	16	0.1311
FEV1.0,% predicted	278	75	±	9.3	7	78	±	10.2	0.4101
DLCO/VA,% predicted	267	82.3	±	24	7	85.2	±	15.6	0.7473
PaO₂(mmHg)	296	60.7	±	18.2	10	80.1	±	11.1	0.0009
PaCO₂(mmHg)	296	37.5	±	4.4	10	37	±	4.2	0.7296
P_VO₂(mmHg)	296	33.1	±	1.2	10	38.2	±	3.9	0.0002
O₂ administration( +)			34 (11.3%)				0(0%)		0.1248
AaDo₂(mmHg)	296	44.8	±	19.1	10	25.9	±	8.1	0.002
WHO-FC (I/II/III/IV)		(3/138/153/7)					(0/9/1/0)		0.0345
Vasodilators( ±)	301	168	/	133	10	3	/	7	0.1049
PEA	301	156	/	145	10	0	/	14	0.0002
BPA	301	52	/	249	10	0	/	14	0.0536
Underlying diseases			(%)				(%)
PE		279	92.7			9	90.0
Pulmonary stenosis		20	6.6			1	10.0
Others		2	0.7			0	0.0

Data are expressed as mean ± SD or n (%). mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; PAWP, pulmonary arterial wedge pressure; CO, cardiac output; 6MWD, 6-min walk distance; %VC, percent vital capacity; FEV1.0%, percent predicted forced expiratory volume in one second; %DLCO/VA, diffusing capacity of carbon monoxide by the alveolar volume; PaO₂, partial pressure of arterial oxygen; PaCO₂, partial pressure of arterial oxygen; PvO₂, mixed venous oxygen tension; AaDO₂, alveolar-arterial oxygen difference; WHO-FC, World Health Organization Functional Class; IPAH, idiopathic pulmonary hypertension; HPAH, hereditary pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; PCH, pulmonary capillary hemangiomatosis; CTD, connective tissue disease; ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; BE, bronchiectasis; PEA, pulmonary endarterectomy; PE, pulmonary embolism

Back to article page

ISSN: 1471-2466

Contact us

Submission enquiries: bmcpulmonarymedicine@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Pulmonary Medicine

Contact us